Alkermes
Manufacturing · Ireland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Connaught House 1 Burlington Rd, Dublin,...Phone Number
+353 17728000Website
www.alkermes.comRevenue
$1.6 BillionStock Symbol
ALKSIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
10
8
1
2
2
2
About Alkermes
Alkermes plc is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such as addiction, schizophrenia, bipolar disorder, opioid dependence and other central nervous system diseases. Its approach integrates scientific research, clinical development and specialised commercial infrastructure to deliver both marketed medicines and investigational candidates, aiming to address serious unmet medical needs and improve how chronic neurological and mental health conditions are managed.Explore more
Alkermes Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alkermes your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Alkermes is spiking on competitors!
Alkermes, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Alkermes has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Alkermes had a recent Job posting/layoffs
Check if Alkermes has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Alkermes recently announced quarterly report
Product Launch: Get notified when Alkermes launches new products
Congratulate Masked Content for being promoted to Masked Content at Alkermes
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Alkermes
Compare insights from companies similar to Alkermes, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alkermes
$1.6B
1K - 5K
Public
$251.2M
1987
Craig HopkinsonExecutive Vice President & Chief Marketing Officer, Research & Development
Company Profile Activity
Activity Insights
Alkermes is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alkermes is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alkermes.
Alkermes financials insights
Gather financial insights about Alkermes, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1991
Stock Offering
$1.2M
2014
Share Placement
$250M
Alkermes Tech Stack
A closer look at the technologies used by Alkermes
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Hiring Plans
Alkermes has more open roles in Finance than it has had at any time in the past 6 months. Areas of expertise include: Regulatory Compliance, Quality Management Systems, Ad Hoc Analysis, External Auditing, Risk Analysis, Requirements Specifications, and Stakeholder Engagement.
Hiring Plans
Person-Based
Events, Doctors / Physicians, Medical Research
Alkermes News & Media
Alkermes CMO sells 9,000 shares, exercises options | ALKS Insider Trading - Stock Titan
Alkermes EVP R&D and CMO Craig Hopkinson exercised 5,000 options at $19.34 and sold 9,000 shares at a $41.67 weighted price under a Rule 10b5-1 plan.These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target - 24/7 Wall St.
The GLP-1 wave has triggered a broader biopharma M&A cycle, and these five biotech companies represent compelling acquisition targets.Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest
Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the growing interest in the orexin receptor agonist market following a pharmaceutical giant’s official foray into the sector. Weight loss drugmaker Eli Lilly and […]Alkermes' CEO Succession Plan | PharmExec - Pharmaceutical Executive Daily
In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus Pharmaceuticals, and Boehringer Ingelheim secures an exclusive license for a preclinical small-molecule program.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alkermes
Sign Up For FreeTo access detailed company insights
Alkermes plc is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such... Read More
